Public Private Partnerships at NIH’s National Center for Advancing Translational Sciences (NCATS) to Translate Promising Therapies into Treatments for Rare and Neglected Diseases

Short bio:
Senior Scientist, Therapeutics for Rare and Neglected Diseases and Director, Portfolio Management and Strategic Operations, National Center for Advancing Translational Sciences, National Institutes of Health
Dr. Yang is a leading expert on improving the efficiency and effectiveness of translational sciences, particularly at the intersection of science and business. She directs initiatives to establish novel public-private partnerships to develop new ways of financing biomedical research that maximize benefits for all stakeholders, particularly underserved patient populations. She uses rare disease drug development projects as case studies to work on common translational medicine issues and simulate solutions to affect biomedical research more broadly. Dr. Yang’s other research interests include quantitative and qualitative portfolio impact analyses to promote real-time and data-driven strategic planning and monitoring as a means to facilitate scientific advances. Prior to joining NIH, Dr. Yang led global teams to contribute to the successful development of novel therapies at Eli Lilly & Co. and Amgen, Inc. She also worked with entrepreneurs and VCs to build startup companies. Nora holds a PhD degree in chemistry from the University of California, San Diego, and a Master’s degree in business management from Stanford University, Graduate School of Business.